These recommendations are extremely important, but can we do more to prevent FN? The use of haematopoietic growth factors will reduce the incidence of both asymptomatic neutropenia and FN (Aapro et al, 2006; Smith et al, 2006) , but it is not practical or costeffective to provide primary prophylaxis for all patients undergoing chemotherapy. As part of the European Union, maybe it is time for the United Kingdom to consider an approach based on the European guidelines for FN prevention (Aapro et al, 2006) . Under these guidelines, patients undergoing chemotherapy are triaged for consideration of primary prophylaxis with growth factors according to the intensity of the regimen and patientspecific risk factors.
In an era when we have the ability to cure more patients and prolong high-quality life for those we cannot cure, it beholds us to make sure that our treatment does not create unnecessary morbidity and mortality.
The articles in this supplement consider the burdens imposed by FN, and the strategies available for preventing as well as providing optimum management for this common side effect of many chemotherapy regimens.
